Journal: Molecular Medicine Reports

Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells

doi: 10.3892/mmr.2018.9730

Figure Lengend Snippet: Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586-1-AP) and TYMS rabbit polyclonal antibody (cat. no. 15047-1-AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

Techniques: Gene Expression, Quantitative RT-PCR, Standard Deviation, Western Blot, Expressing, Control, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: ESMO Open

Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

doi: 10.1016/j.esmoop.2021.100249

Figure Lengend Snippet: Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.

Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

Techniques: Immunohistochemistry

Journal: ESMO Open

Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

doi: 10.1016/j.esmoop.2021.100249

Figure Lengend Snippet: Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.

Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

Techniques: Expressing, Immunohistochemistry

Journal: Molecular medicine reports

Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.

doi: 10.3892/mmr.2018.9730

Figure Lengend Snippet: Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586‐1‐AP) and TYMS rabbit polyclonal antibody (cat. no. 15047‐1‐AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

Techniques: Gene Expression, Standard Deviation, Western Blot, Expressing, Control, Polymerase Chain Reaction

Journal: British Journal of Cancer

Article Title: Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

doi: 10.1038/sj.bjc.6603866

Figure Lengend Snippet: DNA repair ability between TSGH and S3 cells. ( A ) Enhanced DNA repair capacity of CDDP- and oxaliplatin-induced DNA damage by host cell reactivation assay. Percent of repair activity was measured using the undamaged vectors as control. This result is the representative of three independent experiments (mean±s.d.). ( B ) Evaluation of the DNA repairing proteins. The expression levels of ERCC-1 and XRCC-1 were examined in TSGH and S3 cells by Western blot analysis. α -Tubulin has been used as internal control. The results are the representatives of at least three independent experiments.

Article Snippet: Primary antibodies to proteins were purchased from the following companies: ATP7A (BD Transduction Laboratories, Lexington, KY, USA), ATP7B (Novus, Littleton, CO, USA), excision repair cross complementation-1 (ERCC-1) (BD PharMingen, San Diego, CA, USA), TS and glutathione S -transferase- π (GST- π ) (Chemicon, Temecula, CA, USA), α -tubulin (Sigma), and X-ray cross complementation-1 (XRCC-1) (Neomarkers, Fremont, CA, USA).

Techniques: Host-Cell Reactivation, Activity Assay, Expressing, Western Blot

Journal: British Journal of Cancer

Article Title: Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

doi: 10.1038/sj.bjc.6603866

Figure Lengend Snippet: DNA repair ability between TSGH and S3 cells. ( A ) Enhanced DNA repair capacity of CDDP- and oxaliplatin-induced DNA damage by host cell reactivation assay. Percent of repair activity was measured using the undamaged vectors as control. This result is the representative of three independent experiments (mean±s.d.). ( B ) Evaluation of the DNA repairing proteins. The expression levels of ERCC-1 and XRCC-1 were examined in TSGH and S3 cells by Western blot analysis. α -Tubulin has been used as internal control. The results are the representatives of at least three independent experiments.

Article Snippet: Primary antibodies to proteins were purchased from the following companies: ATP7A (BD Transduction Laboratories, Lexington, KY, USA), ATP7B (Novus, Littleton, CO, USA), excision repair cross complementation-1 (ERCC-1) (BD PharMingen, San Diego, CA, USA), TS and glutathione S -transferase- π (GST- π ) (Chemicon, Temecula, CA, USA), α -tubulin (Sigma), and X-ray cross complementation-1 (XRCC-1) (Neomarkers, Fremont, CA, USA).

Techniques: Host-Cell Reactivation, Activity Assay, Expressing, Western Blot

Journal: British Journal of Cancer

Article Title: Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

doi: 10.1038/sj.bjc.6603866

Figure Lengend Snippet: Determination of the expression level of the copper transporters between TSGH and S3 cell. ( A ) Analysis of the expression level of copper uptake transporter CTR1 by using semiquantitative RT–PCR. GAPDH has been used as internal control. The results are the representatives of at least three independent experiments. ( B ) Analysis of the expression level of copper efflux transporters ATP7A and ATP7B by using Western blot analysis. α -Tubulin has been used as internal control. The results are the representatives of at least three independent experiments.

Article Snippet: Primary antibodies to proteins were purchased from the following companies: ATP7A (BD Transduction Laboratories, Lexington, KY, USA), ATP7B (Novus, Littleton, CO, USA), excision repair cross complementation-1 (ERCC-1) (BD PharMingen, San Diego, CA, USA), TS and glutathione S -transferase- π (GST- π ) (Chemicon, Temecula, CA, USA), α -tubulin (Sigma), and X-ray cross complementation-1 (XRCC-1) (Neomarkers, Fremont, CA, USA).

Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot

Journal: British Journal of Cancer

Article Title: Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil

doi: 10.1038/sj.bjc.6603866

Figure Lengend Snippet: Effect of ATP7A-targeted siRNA on sensitivity of S3 cells towards oxaliplatin and CDDP. ( A ) Western blot analysis of S3 cells after treatment with an ATP7A-targeted siRNA. Cells were incubated in the absence or presence of ATP7A siRNA ON-TARGET plus SMART pool for the indicated times, and harvested and lysed for Western blot analysis. α -Tubulin as internal control. ( B ) Effect of ATP7A-targeted siRNA on sensitivity of S3 cells towards oxaliplatin and CDDP. S3 cells were transiently transfected with ATP7A-targeted siRNA for 9 h, then cells were exposed to oxaliplatin and CDDP for another 72 h. Cell growth was determined by methylene blue dye assay. Each value represents the mean of three independent experiments.

Article Snippet: Primary antibodies to proteins were purchased from the following companies: ATP7A (BD Transduction Laboratories, Lexington, KY, USA), ATP7B (Novus, Littleton, CO, USA), excision repair cross complementation-1 (ERCC-1) (BD PharMingen, San Diego, CA, USA), TS and glutathione S -transferase- π (GST- π ) (Chemicon, Temecula, CA, USA), α -tubulin (Sigma), and X-ray cross complementation-1 (XRCC-1) (Neomarkers, Fremont, CA, USA).

Techniques: Western Blot, Incubation, Transfection